The synergistic interplay between cortisol and aldosterone plays a pivotal role in maintaining homeostasis, particularly in regulating blood pressure, electrolyte balance, and stress responses [1]. Cortisol, a glucocorticoid produced by the adrenal cortex, primarily influences glucose metabolism, inflammation, and immune response, while aldosterone, a mineralocorticoid, controls sodium and potassium levels, thereby affecting fluid balance and blood pressure [2]. These two hormones often work in tandem, with cortisol enhancing aldosterone effects on sodium reabsorption in the kidneys [1, 2].

During stress, cortisol levels rise, which can potentiate aldosterone actions, leading to an increase in sodium retention and, consequently, blood volume and pressure. This relationship is particularly significant in situations of physical or emotional stress, where both hormones coordinate to ensure adequate blood flow and energy availability [3]. Moreover, dysregulation in their interplay can contribute to various pathological conditions. For instance, hyperaldosteronism and Cushing’s syndrome, where overproduction of aldosterone and cortisol occurs respectively, are associated with hypertension and metabolic imbalances [4]. Understanding this hormonal synergy is crucial in developing targeted therapies for conditions like heart failure, hypertension, and metabolic disorders.

Lee et al. present an in-depth examination of the synergistic effects of autonomous cortisol secretion (ACS) and aldosterone on vascular calcification, particularly in the context of hyperaldosteronism. The researchers aim to clarify how dysregulated cortisol secretion, which often accompanies primary aldosteronism (PA), influences vascular calcification, a key factor in cardiovascular morbidity [5]. Through a combination of in vivo studies using a patient cohort and in vitro experiments with human aortic smooth muscle cells (HAOSMCs), the study provides valuable insights into the mechanisms by which cortisol and aldosterone interact to promote vascular calcification. This research fills an important gap in our understanding of endocrine influences on cardiovascular disease, especially in patients with PA, where the cardiovascular risks are often underappreciated.

While the most impressive strength of this study lies in its clear and focused research question. The authors effectively address a significant clinical issue, namely, how concurrent ACS, commonly seen in patients with PA, exacerbates the vascular calcification process [6]. Vascular calcification, as an indicator of atherosclerosis, directly correlates with cardiovascular disease risk, making this study highly relevant in both endocrinology and cardiovascular medicine [7]. By leveraging a cohort of 339 patients with PA, the study provides a robust dataset to explore the relationship between cortisol secretion and vascular health. The use of the low-dose dexamethasone suppression test (DST) to define ACS adds clinical precision to the study, ensuring that the patient stratification accurately reflects those with cortisol dysregulation. Additionally, the quantitative analysis of abdominal aortic calcification (AAC) scores via computed tomography (CT) provides a well-established metric to assess vascular calcification, further strengthening the study’s methodological rigor [5].

A notable aspect of this research is the integration of both in vivo patient data and in vitro mechanistic experiments. While the patient data provide clinical relevance, the in vitro experiments allow the authors to delve deeper into the molecular mechanisms underlying their observations. Specifically, the use of HAOSMCs offers a clear window into how cortisol and aldosterone interact at the cellular level to drive calcification. This dual approach not only strengthens the validity of conclusions in the study but also enhances its impact by offering both clinical and mechanistic insights. The study shows that cortisol and aldosterone synergistically promote calcification through mineralocorticoid receptor (MR)-dependent pathways, a novel finding that may have therapeutic implications [8]. By demonstrating that MR antagonism via eplerenone effectively attenuates this calcification, the study suggests a potential therapeutic strategy for mitigating cardiovascular risk in patients with ACS and PA (Fig. 1).

Fig. 1
figure 1

Interplay synergism between cortisol and aldosterone

Full size image

Despite these strengths, there are several areas where the study could be concerned. One of the main limitations of the study is the relatively small sample size of the PA/ACS group. While the overall cohort of 339 patients is commendable, only 65 of these patients had concurrent ACS. This small sample size limits the statistical power of the study, particularly when attempting to draw conclusions about the independent effects of ACS on vascular calcification.

Future studies should aim to replicate these findings in larger, multicenter cohorts to ensure that the observed associations hold across diverse populations. On the other hand, long-term follow-up data on cardiovascular outcomes will be pivotal to assess the long-term cardiovascular risks associated with ACS and the potential benefits of MR antagonist therapy. Without longitudinal data, it is difficult to determine whether the attenuation of vascular calcification through MR antagonism would translate into meaningful reductions in cardiovascular events, such as myocardial infarction or stroke.

While the focus on PA/ACS is well-justified, ACS can occur in other clinical contexts, such as in patients with adrenal incidentalomas or subclinical Cushing’s syndrome. Exploring how findings in this study might apply to these broader populations could provide additional avenues for future research and clinical application. Given the increasing recognition of cortisol dysregulation as a cardiovascular risk factor, the implications of this study extend beyond the PA population and could inform treatment strategies for a wider range of patients.

In conclusion, this research did offer a valuable contribution to the understanding of how ACS and aldosterone interact to promote vascular calcification in patients with primary aldosteronism.